Psychosocial intervention utilization and substance abuse treatment outcomes in a multisite sample of individuals who use opioids

There are several relatively safe and effective FDA-approved medications for Opioid Use Disorder (OUD). Despite the existence of these medications, the rate of returning to opioid use after treatment is relatively high, underscoring the need for continued enhancement of treatments. Adjunctive psycho...

Full description

Saved in:
Bibliographic Details
Published in:Journal of substance abuse treatment 2020-05, Vol.112, p.68-75
Main Authors: Harvey, Laura M., Fan, Weihua, Cano, Miguel Ángel, Vaughan, Ellen L., Arbona, Consuelo, Essa, Saman, Sanchez, Helen, de Dios, Marcel A.
Format: Article
Language:English
Subjects:
12-Step
Abstinence
Analgesics
Buprenorphine
Clinical outcomes
Counseling
Drug abuse
Drugs
Employment
Employment status
Group counseling
Group therapy
Growth models
Medical treatment
Medications for opioid use disorder
Naloxone
Naltrexone
Narcotics
Opiates
Opioid use disorder
Opioids
Participation
Psychosocial factors
Psychosocial intervention
Psychosocial interventions
Psychosocial therapy
Substance abuse treatment
Substance use disorder
Treatment methods
Treatment outcomes
Twelve step model
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:There are several relatively safe and effective FDA-approved medications for Opioid Use Disorder (OUD). Despite the existence of these medications, the rate of returning to opioid use after treatment is relatively high, underscoring the need for continued enhancement of treatments. Adjunctive psychosocial interventions paired with medication have been shown to improve OUD treatment outcomes. However, studies have yet to conclusively examine the distinct effects of the most widely utilized psychosocial treatment modalities. The current study will investigate the relationship between individual counseling, group therapy, and 12-Step participation and illicit opioid abstinence at the end of treatment, 1 and 3 months after treatment. A secondary analysis was conducted with data from a sample of 570 individuals diagnosed with OUD who were recruited from eight substance abuse treatment centers in the United States. Participants were enrolled in a two-group randomized, controlled trial testing buprenorphine-naloxone versus extended-release naltrexone for OUD. A two-level hierarchical linear growth model was used to examine the effects of individual counseling, group therapy, and 12-Step participation on illicit opioid abstinence (urinanalyses) 1- and 3-months post-treatment. Hours of individual counseling and 12-Step participation significantly predicted abstinence at follow-up (p 
ISSN:0740-5472
1873-6483
DOI:10.1016/j.jsat.2020.01.016